Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLX-2508 in healthy adults
NCT07873671Phase 1Not yet recruiting
- Sponsor
- Atridia Pty Ltd
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RLX-2508 in influenza (4 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Treatment Emergent Adverse Events at Day 450. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
RLX-2508
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07873671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873671.